Onyx Rises as Drug Outperforms Pfizer’s in Liver Cancer Trial
April 23 (Bloomberg) — Onyx Pharmaceuticals Inc. increased the most in nine months after its Nexavar treatment for advanced liver cancer outperformed a potential competitor from Pfizer Inc. in trials.

Read more on Bloomberg